We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

168 hedge funds and large institutions have $704M invested in Vanda Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 78 increasing their positions, 44 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 44

18% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 22

2% more funds holding

Funds holding: 164 → 168 (+4)

3.06% less ownership

Funds ownership: 102.51% → 99.45% (-3.1%)

7% less capital invested

Capital invested by funds: $759M → $704M (-$55.4M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

70% less call options, than puts

Call options by funds: $378K | Put options by funds: $1.27M

Holders
168
Holders Change
+4
Holders Change %
+2.44%
% of All Funds
3.68%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
26
Increased
78
Reduced
44
Closed
22
Calls
$378K
Puts
$1.27M
Net Calls
-$889K
Net Calls Change
-$640K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$9.73M
2
Prudential Financial
Prudential Financial
New Jersey
+$8.39M
3
Renaissance Technologies
Renaissance Technologies
New York
+$5.72M
4
Marshall Wace
Marshall Wace
United Kingdom
+$5.66M
5
AC
Armistice Capital
New York
+$5.44M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$51.1M
2
SCM
Stonepine Capital Management
Oregon
-$18.9M
3
Deutsche Bank
Deutsche Bank
Germany
-$9M
4
PAI
Palo Alto Investors
California
-$6.6M
5
GT
Glenmede Trust
Pennsylvania
-$5.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$5.49M +$5.04M +361,974 +703%
Fidelity Investments
27
Fidelity Investments
Massachusetts
$5.29M -$1.96M -140,500 -26%
Two Sigma Advisers
28
Two Sigma Advisers
New York
$5.02M -$588K -42,200 -10%
Ameriprise
29
Ameriprise
Minnesota
$4.78M -$330K -23,655 -6%
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$3.84M +$3.74M +268,413 +1,306%
CS
31
Candriam SCA
Luxembourg
$3.6M – – –
Squarepoint
32
Squarepoint
New York
$3.43M +$2.44M +175,213 +211%
Russell Investments Group
33
Russell Investments Group
United Kingdom
$3.35M +$1.09M +78,037 +45%
Los Angeles Capital Management
34
Los Angeles Capital Management
California
$3.1M +$2.76M +197,952 +558%
Two Sigma Investments
35
Two Sigma Investments
New York
$3.06M -$2.95M -211,463 -48%
Bank of America
36
Bank of America
North Carolina
$3M -$3.39M -243,589 -52%
Point72 Asset Management
37
Point72 Asset Management
Connecticut
$2.97M +$3.11M +223,375 New
BIM
38
Bogle Investment Management
Massachusetts
$2.87M +$3.01M +215,936 New
American Century Companies
39
American Century Companies
Missouri
$2.8M +$2.93M +210,540 New
JP Morgan Chase
40
JP Morgan Chase
New York
$2.7M -$1.36M -97,602 -32%
SEI Investments
41
SEI Investments
Pennsylvania
$2.59M +$204K +14,604 +8%
CCM
42
Cadence Capital Management
Massachusetts
$2.29M -$93.2K -6,690 -4%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$2.17M +$69.6K +4,995 +3%
3C
44
361 Capital
Colorado
$2.17M +$2.28M +163,333 New
GAM
45
Gotham Asset Management
New York
$2.16M +$1.77M +127,061 +357%
QI
46
QS Investors
New York
$2M +$2.79K +200 +0.1%
BFM
47
Boothbay Fund Management
New York
$1.98M +$392K +28,141 +23%
CAM
48
ClariVest Asset Management
California
$1.95M +$457K +32,800 +29%
Rafferty Asset Management
49
Rafferty Asset Management
New York
$1.85M -$84K -6,028 -4%
Public Sector Pension Investment Board (PSP Investments)
50
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$1.8M +$259K +18,556 +16%
1
2
3 4 5

VNDA Hedge Fund Activity: Q3 2019 in Review

168 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2019, worth a combined $704M — down 7.3% from $759M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new VNDA positions and 22 closed out — a net gain of 4 holders — while 78 added to existing stakes and 44 trimmed.

The largest buyer was Vanguard Group, adding an estimated $9.73M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $51.1M sold.

  • 168 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2019, up from 164 in Q2 2019.
  • Funds reported $704M of Vanda Pharmaceuticals stock for Q3 2019, down 7.3% quarter-over-quarter.
  • 26 funds opened new Vanda Pharmaceuticals positions in Q3 2019 and 22 closed out, a net change of +4 holders.
  • The largest Vanda Pharmaceuticals buyer in Q3 2019 was Vanguard Group, an estimated $9.73M added.
  • The largest Vanda Pharmaceuticals seller in Q3 2019 was Consonance Capital Management, an estimated $51.1M sold.

Based on aggregated 13F filings for Q3 2019.